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in descending order of frequency: BSL valve (Odds 3.5 IC 95% [1.3 –
9.6], p¼0.02), presence of an artifact (Odds 2.5 IC 95% [1.2 – 5.4],
p¼0.02) and BMI (Odds 1.1 IC 95% [1.0 – 1.2], p¼0.04).
CONCLUSIONS R-angio with dedicated motion compensation soft-
ware offers good image quality for on-line frame analysis in 72% of the
patients. Image quality predominantly depends on valve type, pres-
ence of artefacts and patient-related variables such as BMI.
“Disclaimer: The concepts and information presented in this paper are
based on research and are not commercially available.”
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BACKGROUND Stroke is a feared complication of trans-catheter aortic
valve replacement (TAVR). Carotid and vertebral artery duplex ul-
trasonography is routinely obtained prior to TAVR, but the signiﬁ-
cance of extracranial carotid and vertebral artery disease (CVD) on the
risk of stroke following TAVR is unknown. The purpose of this study is
to assess the impact of CVD on the risk of stroke following TAVR.
METHODS We reviewed 294 consecutive cases of TAVR at a single
tertiary care academic medical center from June, 2008 to March, 2015.
We included 263 patients who underwent routine carotid and verte-
bral artery duplex ultrasonography prior to TAVR in a retrospective
cohort study. Patients with at least 50% stenosis of a carotid or
vertebral artery were identiﬁed as having CVD, and patients were
stratiﬁed into 2 groups by the presence or absence of CVD. The pri-
mary outcome was stroke within 30 days of TAVR. We adjudicated
stroke by the guideline recommendations of the Valve Academic
Research Consortium. Secondary outcomes included 30-day mortality
and overall survival following TAVR. We used chi2 and Fischer’s exact
tests to compare categorical variables and independent samples t tests
to compare continuous variables. We used Kaplan Meier life table
analysis to assess overall survival. We included univariate predictors
of stroke at P<0.10 in a multivariable logistic regression to identify
predictors of stroke after TAVR.
RESULTS CVD was present in 51 (19%) patients. The CVD group had
higher rates of coronary artery disease, prior coronary artery bypass
surgery, and peripheral artery disease compared to the non-CVD
group. There was no signiﬁcant difference in the rate of prior stroke or
the burden of aortic atheroma by intra-operative trans-esophageal
echocardiogram between CVD and non-CVD patients. Trans-femoral
access was less common in the CVD group (55% vs. 77%, p<0.01).
Stroke occurred in 18 (6.8%) patients within 30 days after TAVR. No
patients with CVD suffered a stroke. There was no difference in 30-
day mortality (10% vs 4%, p¼0.11) and overall survival (log-rank test,
p¼0.89) between the CVD and non-CVD groups. CVD was not a sig-
niﬁcant predictor of stroke following TAVR by logistic regression. In a
multivariable model, there were no signiﬁcant independent pre-
dictors of stroke after TAVR, but baseline antiplatelet therapy showed
a trend towards a protective effect, and higher pre-TAVR mean aortic
valve gradient showed a trend toward increased risk of stroke (table).Predictors of Stroke
Following TAVR Odds Ratio95% Conﬁdence
Interval PPrior coronary artery
bypass surgery0.33 0.04 to 1.89 0.32Prior dyslipidemia 0.40 0.11 to 1.38 0.15Baseline antiplatelet
therapy0.29 0.08 to 1.02 0.05Aortic atherosclerosis
> 2mm thickness3.71 0.68 to 20.12 0.13Trans-aortic access 3.41 0.56 to 20.97 0.19Pre-TAVR mean aortic
valve gradient
(increasing
continuous variable
by mm Hg)1.05 1.00 to 1.11 0.07CONCLUSIONS CVD is not associated with an increased risk of stroke
or death following TAVR. The routine screening of CVD prior to TAVR
does not appear justiﬁed.
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BACKGROUND Patients with severe aortic stenosis who are referred
for transcatheter aortic valve replacement (TAVR) need to meet aortic
root and aortic annular anatomical inclusion criteria. We sought to
characterize the number of patients that could not have the currently
available transcatheter valves (Sapien XT and CoreValve).
METHODS We screened 400 patients with severe aortic stenosis who
were referred for TAVR between 2010-2014 who had had multi-de-
tector computed tomographic (MDCT) imaging. Annulus measure-
ments of the basal ring (short- and long-axis, area-derived diameter),
coronary ostia height, sinus area (SA), sino-tubular junction area
(STJ), calciﬁcation and eccentricity index (EI, 1-short axis/long axis)
were made.
RESULTS The vast majority of patients were able to be offered a
currently available TAVR valve (88%). We identiﬁed 49 patients who
were excluded for anatomical annular characteristics alone. Large
aortic annuli were the most common reason for anatomical exclusion
[704  79 mm2; (n¼ 39, 80 %)]. In addition these large annuli were
more elliptical (EI, 1.39  0.1) with more eccentric calciﬁcation (68 %).
The presence of low coronary heights (n¼6 mm: n¼19, 18 %) from the
aortic annular plane was the next most common reason. The left main
coronary artery was more commonly lower than the right coronary
artery and low coronary heights with effaced coronary sinuses
appeared occur together (n¼11, 57 %). Small aortic annuli were the
least common [290  50 mm2; n¼1, 2 %) cause for exclusion from
TAVR therapy. None of the patients who were excluded form TAVR
therapy had more than one annular reason for TAVR exclusion.
CONCLUSIONS Most patients with severe aortic stenosis who are
referred for TAVR can be offered a transcatheter valve. However, 12 %
of patients cannot be offered a therapy due to annular anatomical
exclusion criteria. This was primarily due to the presence of large
aortic annuli and low coronary heights.
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BACKGROUND The repositionable, fully retrievable, CE-marked
Lotus Valve is designed to facilitate controlled, precise positioning
and minimize paravalvular aortic regurgitation. Results to 3 years
post-implantation with Lotus have not yet been reported.
METHODS REPRISE I is a prospective, single-arm, 3-center feasibility
study designed to assess acute safety and performance of the 23mm
Lotus Valve in symptomatic patients with calciﬁed aortic stenosis who
were considered high surgical risk by the Heart Team.
RESULTS The Lotus Valve was implanted in 11 female patients with a
mean age 83.03.6 years and a mean STS score 4.92.5%). Frailty
measures included gait speed 6s (9/11), grip strength 18kg
(7/11), and cognitive dysfunction (5/11; deﬁned as a score <4 on the
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successfully implanted with a Lotus Valve with no procedural mor-
tality. All patients remained alive at 2 years, and the 2-year clinical
follow-up and TTE assessment rates were 100% (11/11). Major stroke
occurred in 1 patient on day 3, for a 2-yearmajor stroke rate of 9.1%, and
life-threatening/disabling bleeding occurred in 2 patients for a 2-year
rate of 18.2%. Conduction disturbance requiring new permanent
pacemaker implantation remained at 4 patients. There were no repeat
hospitalizations for valve-related symptoms or cardiac decompensa-
tion. Mean aortic gradient was 15.54.4mmHg and mean effective
oriﬁce area was 1.510.19cm2 at 2 years. All (100%) patients remained
in New York Heart Association Class I or II. Core laboratory adjudicated
paravalvular aortic regurgitation was not evaluable in 1 patient, trace/
trivial in 1 patient, mild in 1 patient, and absent in 8 patients at 2 years.
CONCLUSIONS Two-year feasibility results suggest that the Lotus
Valve has minimal aortic regurgitation and low clinical event rates
sustained through 2 years. Three-year outcomes from REPRISE I will
be available for presentation for the ﬁrst time at TCT 2015.
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BACKGROUND With the beginning of transcatheter aortic valve im-
plantation (TAVI), the use of active-ﬁxation leads combined with
externalized re-usable permanent pacemakers was initiated to
improve lead stability, increase patient mobility and facilitate
handling for nursing staff. Experience and beneﬁts of temporary
permanent pacemaker (TPPM) systems have thus far mainly been
reported in patients suffering from cardiovascular implantable elec-
tronic device (CIED) infection. The aim was to investigate the safety
and efﬁcacy of TPPMs for periprocedural rapid ventricular pacing and
postprocedural back-up pacing in patients undergoing transcatheter
aortic valve implantation (TAVI).
METHODS Between November 2008 and April 2015, a temporary
permanent pacemaker system was implanted in 108 consecutive TAVI
patients. An active-ﬁxation right-ventricular lead was implanted in
either an apical or septal position via the right internal jugular vein
using a 7 French peel-away introducer sheet. Pacing treshold was
considered acceptable if <1.0 V at a pulse width of 0.5 ms, as were R-
wave sensing amplitudes > 10 mV. The lead was then sutured to the
patient’s neck and connected to a re-usable permanent pacemaker
programmed in VVI mode. Finally, the pacemaker and lead were
taped to the patient’s skin in typical infraclavicular position.RESULTS Mean patients’ age was 81.1  4.9 years and mean dura-
tion of TPPM was 5.6  2.1 (range 2-14) days. After successful pri-
mary implantation in all patients without any procedure-related
complications deﬁned as pneumothorax, pericardial effusion with
hemodynamic relevance and local infection or hematoma, lead
dislocation and necessity of lead repositioning occurred in one
patient (0.92%).Patients 108Male (female) 44 (64)Age (years) 81.1  4.9
Success of temporary lead implantation, n (%) 108 (100)Apical positioning, n (%) 68 (63)Septal positioning, n (%) 40 (37)No. of days TPPM (range) 5.6  2.1 (2-14)
Procedure-related complications 0Lead dislocation, n (%) 1 (0.92)CONCLUSIONS Temporary permanent pacemakers using active-ﬁxa-
tion leads are safe and effective in TAVI procedure, providing a stable
pacing mechanism with a low rate of lead dislocation.
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BACKGROUND Different studies have compared the rate of more-
than-mild aortic regurgitation (AR) between Corevalve (MCS) and
Edwards-SAPIEN valve (ESV) with different results. Aortic root calci-
ﬁcation has been also related with AR. For the time being, no study
reported the rate of signiﬁcant AR between these 2 devices in relation
with the aortic root anatomy.
METHODS All consecutive patients (p) who underwent transcatheter
aortic valve replacement (TAVR) with a MCS or ESV (ESV-XT or ESV-
Sapien 3) and a good image quality CT-scan were included. Aortic root
calcium was assessed by using the modiﬁed Agatston score, from left
main to the nadir of the aortic annulus leaﬂets. Paravalvular AR was
assessed by aortography at least 10 minutes post TAVR. Based on
annulus eccentricity and Agatston score 4 phenotypes (Ph) were
identiﬁed: - Ph 1: Mildly calciﬁed aortic root and circular annulus. - Ph
2: Mildly calciﬁed aortic root and elliptical annulus. - Ph 3: Severely
calciﬁed aortic root and circular annulus. - Ph 4: Severely calciﬁed
aortic root and elliptical annulus.
RESULTS A total of 248 p were included in the analysis (MCS¼196;
ESV 52). The distribution of phenotypes was as follows: for ES, ph 1
was present in 13 p (25.0 %), ph 2 in 13 p (25.0%), ph 3 in 14 p (26.9 %)
and ph 4 in 12 p (23.1%). For MCS ph 1 was present in 59 p (30.1 %), ph 2
in 46 (23.5 %), ph 3 in 49 p (25.0%) and ph 4 in 42 p (21.4 %). Seventy-
one p (28.6 %) patients had more than mild paravalvular AR, 7.7 % of
patients with ES (4 p.) and 28.6 % (67 p) with MCS. Overall, Agatston
score (4204  1990 vs. 3433  3269, p¼0.065) and eccentricity of the
annulus (18.9  8.2 vs. 15.9  8.5, p¼0.092) were higher in patients
with more-than-mild AR. In mildly calciﬁed aortic roots, there were
not differences between both devices in the rate of signiﬁcant AR
(MCS 16.2 % vs. ESV 11.5%, p¼0.56). In severely calciﬁed aortic roots,
more than mild AR was more frequent after TAVR with MCS (MCS
54.9% vs. ESV 4.0 %, p¼< 0.0001). In the analysis per ph, there were
not signiﬁcant differences in the rate of AR per device for phenotype 1
and 2. In ph 3 and 4 more than mild paravalvular AR was more
frequent with MCS (Figure).
CONCLUSIONS In heavily calciﬁed roots, TAVR with ESV seems to be
associated with less paravalvular AR in comparison with MCS. In
mildly calciﬁed aortic roots the rate of signiﬁcant AR is similar be-
tween both devices.
